Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.

This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early response to epoetin… in this case at 4 weeks. Sadly, we still know that about two thirds of patients respond, but we cannot predict at the outset who the responders and non-responders will be at the current doses and dosing frequencies.

– David H. Henry